Beijing Mabworks Biotech Co., Ltd.
Quick facts
Phase 3 pipeline
- lenalinomide · Other
- mil60 · Oncology
mil60 is a monoclonal antibody targeting the PD-1 receptor. - MIL62 · Immunology
MIL62 is a monoclonal antibody targeting IL-6 receptor to inhibit interleukin-6 signaling and reduce inflammatory responses.
Phase 1 pipeline
- MBS303
- MIL116
- Recombinant Humanized Monoclonal Antibody MIL93
- Recombinant Humanized Monoclonal Antibody MIL95
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Beijing Mabworks Biotech Co., Ltd. portfolio CI brief
- Beijing Mabworks Biotech Co., Ltd. pipeline updates RSS
Frequently asked questions about Beijing Mabworks Biotech Co., Ltd.
What is Beijing Mabworks Biotech Co., Ltd.'s pipeline?
Beijing Mabworks Biotech Co., Ltd. has 3 drugs in Phase 3, 0 in Phase 2, 4 in Phase 1. Late-stage candidates include lenalinomide, mil60, MIL62.
Related
- Sector hub: All tracked pharma companies